egfr mutation positive tumors: treatment strategies in front line and at relapse
Published 7 years ago • 9K plays • Length 23:10Download video MP4
Download video MP3
Similar videos
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
20:24
targeted treatment with egfr tkis: front line options
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
12:11
clinical clips in nsclc harboring egfr mutations: cutting-edge reports from asco 2024
-
2:46
gefitinib: targeted treatment for egfr mutation-positive lung cancer | glpbio
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
1:41
egfr mutations in patients with lung cancer
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
6:41
egfr-positive nsclc: treatment at progression
-
3:41
how do doctors treat lung cancer with egfr mutations?
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
5:18
case based panel discussion - egfr mutation -the recommended treatment for common egfr mutations
-
2:00
choosing first line therapy in egfr mutations
-
10:30
tumor clonality in egfr mutation-positive nsclc
-
12:20
podcasts in nsclc harboring egfr mutations: cutting-edge reports from asco 2024 - episode 1
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
1:56
what targeted therapies are used for people with the egfr mutation?